Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$5.36 USD

5.36
267,519

-0.16 (-2.90%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $5.34 -0.02 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Agenus (AGEN) Reports Wider than Expected Q4 Loss, Sales Miss

by Zacks Equity Research

Agenus reports wider than expected loss and misses sales estimates in the fourth quarter of 2017.

    Zacks Equity Research

    What's in Store for Agenus (AGEN) This Earnings Season?

    by Zacks Equity Research

    Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.

      Zacks Equity Research

      Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

        Zacks Equity Research

        Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why

        by Zacks Equity Research

        Spectrum Pharmaceuticals (SPPI) stock is witnessing significant momentum mainly on encouraging data from poziotinib study.

          Zacks Equity Research

          BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

          by Zacks Equity Research

          BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

            Zacks Equity Research

            Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%

            by Zacks Equity Research

            Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares more than 11% on the day amid huge volumes.

              Zacks Equity Research

              Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

              by Zacks Equity Research

              Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.

                Zacks Equity Research

                Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

                by Zacks Equity Research

                Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.

                  Zacks Equity Research

                  Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

                  by Zacks Equity Research

                  Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

                    Zacks Equity Research

                    Agenus (AGEN) Reports In Line Q3 Loss, Sales Miss Estimates

                    by Zacks Equity Research

                    Agenus reported in line loss in the third quarter of 2017 but sales missed expectations.

                      Zacks Equity Research

                      Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

                      by Zacks Equity Research

                      Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.

                        Zacks Equity Research

                        What's in Store for Ligand (LGND) This Earnings Season?

                        by Zacks Equity Research

                        Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.

                          Zacks Equity Research

                          What's in Store for Madrigal (MDGL) This Earnings Season?

                          by Zacks Equity Research

                          Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.

                            Zacks Equity Research

                            Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?

                            by Zacks Equity Research

                            Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.

                              Zacks Equity Research

                              What's in Store for Catalyst (CPRX) This Earnings Season?

                              by Zacks Equity Research

                              Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

                                Zacks Equity Research

                                What's in the Cards for Merrimack (MACK) in Q3 Earnings?

                                by Zacks Equity Research

                                Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                                  Zacks Equity Research

                                  What's in the Cards for Repros (RPRX) This Earnings Season?

                                  by Zacks Equity Research

                                  Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                                    Zacks Equity Research

                                    Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates

                                    by Zacks Equity Research

                                    Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.

                                      Zacks Equity Research

                                      Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

                                      by Zacks Equity Research

                                      Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

                                        Zacks Equity Research

                                        Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

                                        by Zacks Equity Research

                                        Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                                          Zacks Equity Research

                                          Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?

                                          by Zacks Equity Research

                                          Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.

                                            Zacks Equity Research

                                            AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook

                                            by Zacks Equity Research

                                            AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.

                                              Zacks Equity Research

                                              Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)

                                              by Zacks Equity Research

                                              Horizon Pharma???s shares have declined 12% in the year so far, underperforming the industry???s gain of 0.9%.

                                                Zacks Equity Research

                                                Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3

                                                by Zacks Equity Research

                                                Epizyme (EPZM) posted narrower-than-expected loss in the third quarter of 2017. It plans to meet the FDA to begin the registration strategy for its lead pipeline candidate, tazemetostat, in the next quarter.

                                                  Zacks Equity Research

                                                  Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

                                                  by Zacks Equity Research

                                                  Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.